# Chongqing Porton Fine Chemicals Chongqing Porton Fine Chemicals is a Portfolio Company based in Chongqing, China. ## Overview - **Organization type:** Portfolio Company - **Headquarters:** Chongqing, China - **Region:** Asia - **Address:** Chongqing, China - **Founded:** 2005 - **Assets under management:** Undisclosed - **Website:** porton.cn ## Regulatory record - **Reports private funds:** No ## About Founded in 2005, Chongqing Porton Fine Chemicals emerged from China's western industrial base in Chongqing to provide outsourced pharmaceutical R&D and production. The firm supplies pharmaceutical intermediates and active pharmaceutical ingredients (APIs) to biopharmaceutical companies globally, with a portfolio concentrated on innovative drugs targeting infectious diseases. Its early anchor was process chemistry for antiviral therapies, a positioning that gave Porton entry into Western biotech supply chains early in the CDMO outsourcing wave. Porton's strategy rests on the CDMO spectrum — from route scouting and process development through to pilot-scale and commercial cGMP manufacturing. The firm covers small-molecule APIs and advanced intermediates, with disclosed capacity for multi-ton production of high-potency compounds. Therapeutic focus areas include antivirals for HIV and hepatitis C, metabolic disease treatments, and oncology agents. Porton supplies Gilead Sciences with a key intermediate for hepatitis C combination therapies, a relationship that put the firm on global allocator watchlists when Sovaldi and Harvoni regimens reshaped antiviral care. The company also holds relationships with European and US emerging biotechs that require rapid scale-up from preclinical chemistry to Phase III supply. Geographically, it operates from its Chongqing headquarters complex and serves clients across North America, Europe, and Japan — export manufacturing accounts for the bulk of revenue. Porton is publicly traded on the Shenzhen Stock Exchange under ticker 300363, with a market capitalization that has fluctuated with the biotech cycle. The firm employs a technical workforce of process chemists, engineers, and quality-assurance personnel spread across multiple Chongqing sites. Adjacent to its API business, Porton has expanded into formulation development and analytical services, mirroring the vertical integration path of larger CDMO peers. Capital investment in recent years has centered on expanding high-containment manufacturing suites for oncology APIs and upgrading quality systems to meet evolving FDA and EMA inspection standards. Structurally, Porton represents a distinct category in Chinese pharmaceutical outsourcing: an independent, publicly listed CDMO whose fortunes are tied to foreign innovative drug pipelines rather than to domestic generic volume. Its Chongqing location gives it cost advantages over coastal operations while challenging it to attract top-tier process development talent. The firm's regulatory history includes multiple FDA inspections and establishment of drug master files with the US regulator, making it a credible supplier in the global small-molecule supply chain. ## Sectors - Healthcare Services - Industrial Tech ## Questions ### What is Porton's core business model? Porton operates as a contract development and manufacturing organization for small-molecule pharmaceutical intermediates and active pharmaceutical ingredients. The firm takes client drug candidates from early process chemistry through to commercial-scale cGMP manufacturing. Revenue is concentrated in custom synthesis and supply agreements with foreign innovative drug companies, particularly in antiviral and oncology therapeutic areas. ### What therapeutic areas does Porton focus on? Porton's chemical-manufacturing expertise concentrates on antiviral therapeutics, targeting HIV and hepatitis C, alongside oncology agents and treatments for metabolic disease. The firm handles small-molecule APIs that often require complex multi-step synthesis — the kind of chemistry where its Chongqing-based technical workforce has built deep know-how over two decades. This focus on innovative, rather than generic, molecules differentiates Porton from lower-cost Chinese fine-chemical suppliers. ### How does Porton compare to larger Chinese CDMOs like WuXi or Asymchem? Porton operates at a smaller scale than WuXi AppTec or Asymchem but competes in the same global small-molecule CDMO segment. Porton's differentiation lies in its geographic base in Chongqing — offering lower operating costs than coastal competitors — and its historical anchor in antiviral chemistry, which built a specialist reputation. The firm lacks the broad service portfolio of the largest peers but maintains credible FDA and EMA quality standing that keeps it in Western supply chains. ## Related profiles - [Garch Capital](https://altss.com/profile/garch-capital) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/chongqing-porton-fine-chemicals-co-ltd Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology